New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: Case of enalapril and benazepril in dogs

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 3, 2000, Pages 1094-1103

  Toutain, Pierre Louis ^a   Lefebvre, Hervé P ^a   Laroute, Valérie ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; DOG; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE; KIDNEY INJURY; MALE; NEPHRECTOMY; NONHUMAN; OXYGEN AFFINITY; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZAZEPINES; DOGS; ENALAPRIL; FEMALE; KIDNEY FAILURE; MODELS, BIOLOGICAL; PRODRUGS; REGRESSION ANALYSIS;

EID: 0034089877     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Begg EJ, Bailey RR, Lynn KL, Robson RA, Frank GJ and Olson SC (1989) The pharmacokinetics of angiotensin converting enzyme inhibitors in patients with renal impairment. J Hypertens 7 (Suppl 5):S29-S32.
2. Duffee NE, Bevill RF, Koritz GD and Schaeffer DJ (1990) An experimental model for pharmacokinetic analysis in renal failure. J Pharmacokinet Biopharm 18:71-86.
3. Francis RJ, Brown AN, Kler L, Fasanella d'Amore T, Nussberger J, Waeber B and Brunner HR (1987) Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: Development of a mathematical model. J Cardiovasc Pharmacol 9:32-38.
4. Gibaldi M and Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York.
5. Hersh AD, Kelly JG, Laher MS, Carmody M and Doyle GD (1996) Effect of hydrochlorothiazide on the pharmacokinetics of enalapril in hypertensive patients with varying renal function. J Cardiovasc Pharmacol 27:7-11.
6. Hooper NM (1993) Ectopeptidases, in Biological Barriers to Protein Delivery (Audus KL and Raub TJ eds) pp 23-50 Plenum Press, New York.
7. Hoyer J, Schulte KL and Lenz T (1993) Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet 24:230-254.
8. Jayewardene AL, Seneviratne AK and Gambertoglio JG (1994) Paired in reverse-phase HPLC assay for the simultaneous determination of iothalamic acid and para-aminohippuric acid in plasma. J Chromatogr 17:2395-2412.
9. Kaiser G, Ackermann R and Sioufi A (1989) Pharmacokinetics of a new angiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special populations. Am Heart J 117:746-751.
10. Kelley J, Doyle G, Donohoe J, Laher M, Vandenburg MJ, Currie WJC and Cooper WD (1984) The pharmacokinetic profile of enalaprilat in normal subjects and patients with renal impairment. Br J Clin Pharmacol 18:P274.
11. Kelly J, Doyle G, Donohoe J, Laher M, Vandenburg MJ, Currie WJC and Cooper WD (1985) Chronic dose pharmacokinetic of enalapril in renal impairment. Br J Clin Pharmacol 20:P264-P265.
12. Koeppe P and Hamann C (1980) A program for non-linear regression analysis to be used on desk-top computers. Comput Programs Biomed 12:121-128.
13. Lees KR, Kelman AW, Reid JL and Whiting B (1989) Pharmacokinetics of an ACE inhibitor, S-9780, in man: Evidence of tissue binding. J Pharmacokinet Biopharm 17:529-550.
14. Lefebvre H, Laroute V, Concordet D and Toutain PL (1999) Effects of renal impairment on the disposition of orally administered enalapril, benazepril and their active metabolites. J Vet Intern Med 13:21-27.
15. MacFadyen RJ, Meredith PA and Elliott HL (1993) Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships, an overview. Clin Pharmacokinet 25:274-282.
16. Meredith PA, Grass P, Guitard C and Elliott HL (1994) Pharmacokinetics of spirapril in renal impairment. Blood Pressure 3 (Suppl 2):14-19.
17. Oguchi H, Miyasaka M, Koiwai T, Tokunaga S, Hora K, Sato K, Yoshie T, Shioya H and Furuta S (1993) Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency. Clin Pharmacokinet 24:421-427.
18. Sioufi A, Pommier F, Gauducheau N, Godbillon J, Bodin F and Darragon T (1992) Pharmacokinetics of benazepril and benazeprilat in hypertensive patients with renal impairment during one year treatment with daily doses of 10 mg of benazepril hydrochloride, in Pharmacocinétique: de la Recherche à la Clinique (Bres J and Panis G eds) pp 330-340, John Libbey Eurotext, Montrouge, France.
19. Sioufi A, Pommier F, Kaiser G and Dubois JP (1988) Determination of benazepril, a new angiotensin converting enzyme inhibitor, and its active metabolite, benazeprilat, in plasma and urine by capillary gas-chromatography-mass selective detection. J Chromatogr Biomed Appl 434:239-246.
20. Tocco DJ, deLuna FA, Duncan AEW, Vassil TC and Ulm EH (1982) The physiological disposition and metabolism of enalapril maleate in laboratory animals. Drug Metab Dispos 10:15-19.
21. Toutain, P-L, Lefebvre HP and King JN (2000) Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. J Pharmacol Exp Ther 292:1087-1093.
22. 14C]-benazepril hydrochloride in rat, dog and baboon. Absorption, distribution, kinetics, biotransformation and excretion. Arzneim-Forsch 39:62-67.